Todd Harris
Founder chez TYRA BIOSCIENCES, INC.
Fortune : 25 M $ au 31/03/2024
Profil
Todd J.
Harris is the founder of Tyra Biosciences, Inc. (founded in 2018) and Sienna Biopharmaceuticals, Inc. (founded in 2010).
He is currently the President, CEO, Treasurer & Director at Tyra Biosciences, Inc. and the Director & Head-Corporate Development at Sienna Biopharmaceuticals, Inc. Additionally, Dr. Harris is currently working as a Director at Primmune Therapeutics, Inc. since 2019.
Dr. Harris has a doctorate degree from the Massachusetts Institute of Technology, an undergraduate degree from Brigham Young University, and a graduate degree from the University of California San Diego.
Détentions connues dans des sociétés publiques
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
TYRA BIOSCIENCE, INC
2,86% | 26/03/2024 | 1 504 577 ( 2,86% ) | 25 M $ | 31/03/2024 |
Postes actifs de Todd Harris
| Sociétés | Poste | Début |
|---|---|---|
| TYRA BIOSCIENCES, INC. | Founder | 02/08/2018 |
Primmune Therapeutics, Inc.
 Primmune Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Primmune Therapeutics, Inc. develops small molecules, orally administered toll-like receptor for cancer immunotherapy and tumors. The firm offers treatment and prevention of viral infections. The company was founded by Paulo Rangel, James Appleman, and Stephen Webber in October, 2017 and is headquartered in San Diego, CA. | Director/Board Member | 01/10/2019 |
Anciens postes connus de Todd Harris
| Sociétés | Poste | Fin |
|---|---|---|
| SIENNA BIOPHARMACEUTICALS, INC. | Founder | 01/07/2018 |
Formation de Todd Harris
| Massachusetts Institute of Technology | Doctorate Degree |
| Brigham Young University | Undergraduate Degree |
| University of California San Diego | Graduate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 2 |
|---|---|
| SIENNA BIOPHARMACEUTICALS, INC. | Health Technology |
| TYRA BIOSCIENCES, INC. | Health Technology |
| Entreprise privées | 1 |
|---|---|
Primmune Therapeutics, Inc.
Primmune Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Primmune Therapeutics, Inc. develops small molecules, orally administered toll-like receptor for cancer immunotherapy and tumors. The firm offers treatment and prevention of viral infections. The company was founded by Paulo Rangel, James Appleman, and Stephen Webber in October, 2017 and is headquartered in San Diego, CA. | Commercial Services |
